| Diabetes Mellitus, Non-Insulin-Dependent
Basaglar vs Lyumjev
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Basaglar vs Lyumjev with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLyumjev has a higher rate of injection site reactions vs Basaglar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lyumjev but not Basaglar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Basaglar
Lyumjev
At A Glance
SC injection
Once daily
Long-acting insulin analog
SC injection
With each meal
Rapid-acting insulin analog
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Type 1 Diabetes Mellitus Approximately one-third of total daily insulin requirements SC once daily; short- or rapid-acting pre-meal insulin covers the remainder.
Diabetes Mellitus, Non-Insulin-Dependent 0.2 units/kg or up to 10 units SC once daily.
Diabetes Mellitus, Non-Insulin-Dependent Administer U-100 or U-200 SC at meal start or within 20 minutes after starting a meal into abdomen, upper arm, thigh, or buttocks; U-100 also available via CSII insulin pump or IV infusion (under medical supervision, diluted to 1 unit/mL); individualize dose based on metabolic needs and glucose monitoring.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to insulin glargine or any excipient in BASAGLAR
- Episodes of hypoglycemia
- Hypersensitivity to insulin lispro-aabc or any excipient in LYUMJEV
Adverse Reactions
Most common (>=5%) Infection, nasopharyngitis, upper respiratory tract infection
Serious Severe hypoglycemia, anaphylaxis, peripheral edema, lipodystrophy, localized cutaneous amyloidosis
Postmarketing Medication errors (accidental administration of rapid-acting insulin instead of insulin glargine), localized cutaneous amyloidosis, hyperglycemia or hypoglycemia associated with injection site changes
Most common (>=5%) Nasopharyngitis, upper respiratory tract infection, infusion site reaction, infusion site pain
Serious Hypoglycemia (including severe), severe hypersensitivity reactions (anaphylaxis, angioedema, bronchospasm, hypotension, shock)
Postmarketing Localized cutaneous amyloidosis at injection site, hyperglycemia or hypoglycemia associated with injection into areas of localized cutaneous amyloidosis
Pharmacology
Insulin glargine is a long-acting human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production, providing sustained glucose-lowering activity over 24 hours with no pronounced peak.
Rapid-acting human insulin analog that binds insulin receptors to stimulate peripheral glucose uptake in skeletal muscle and fat and inhibit hepatic glucose production, while also inhibiting lipolysis and proteolysis and enhancing protein synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Basaglar
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (6/12) · Qty limit (0/12)
Lyumjev
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (6/12) · Qty limit (8/12)
UnitedHealthcare
Basaglar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Lyumjev
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Basaglar
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Lyumjev
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Basaglar.
No savings programs available for Lyumjev.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BasaglarView full Basaglar profile
LyumjevView full Lyumjev profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.